FINDER SIGNED
FINDER: FIghtiNg DEngue viRus, a novel strategy for the development of fully protective antiviralsthat act by disrupting the DENV NS3/NS5 interaction
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0FINDER project word cloud
Explore the words cloud of the FINDER project. It provides you a very rough idea of what is the project "FINDER" about.
Project "FINDER" data sheet
The following table provides information about the project.
| Coordinator |
CARDIFF UNIVERSITY
Organization address contact info |
| Coordinator Country | United Kingdom [UK] |
| Total cost | 183˙454 € |
| EC max contribution | 183˙454 € (100%) |
| Programme |
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility) |
| Code Call | H2020-MSCA-IF-2017 |
| Funding Scheme | MSCA-IF-EF-ST |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-05-01 to 2020-04-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | CARDIFF UNIVERSITY | UK (CARDIFF) | coordinator | 183˙454.00 |
Map
Project objective
Dengue virus (DENV) is the most prevalent arthropod-borne viral pathogen and infects about 400 million people worldwide every year, causing epidemics that are spreading rapidly, with increased frequency and magnitude. To date, no specific treatments or a fully protective vaccine are available for dengue. In line with the Priority 3 of H2020, the development of effective therapeutic strategies against DENV is urgently needed. The purpose of FINDER is that of developing innovative anti-dengue candidate drugs able to disrupt the protein-protein interactions between the viral NS3 and NS5 proteins, two key and conserved enzymes of DENV replication complex. To this end, some druggable cavities at the NS3/NS5 interface will be identified and an in silico screening of a virtual small molecule library will be performed to search for potential inhibitors of NS3/NS5 interaction. After the selection and the biological characterization of the hits, a hit-to-lead optimization step will be carried out to find compounds with lead-like properties. Such drugs are expected to be endowed with broad-spectrum antiviral activity, a reduced risk for developing resistance and lower undesirable side-effects. Through a comprehensive dissemination and exploitation strategy, one or more drug candidates will be evaluated in the future in animal models and then in clinical trials. The outcomes of this project could fill the gap of the lack of effective anti-DENV drugs, resulting in an enormous impact on world-wide public health, as well as on the European competitiveness in this area. This project will also contribute to strengthen a wide set of skills of the applicant by a multidisciplinary training in the field of antiviral research, which will make him ready for attaining a position of independent researcher. In addition, the complementary competencies between the applicant and the supervisor will allow a two-way transfer of knowledge, leading to a benefit also for the Host Organisation.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FINDER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "FINDER" are provided by the European Opendata Portal: CORDIS opendata.